Vice President and Biotech Analyst Pete Stavropoulos, PhD, hosted the panel “Next Generation Drugs. New Targets and Innovative Approaches for High-unmet Need Epileptic Disorders.” The panel featured Michael Bozik, President of Biohaven, Matthew Leoni, MD, MBA, SVP of Global Clinical Development at Cerevel Therapeutics, Kevin Lind, President & CEO of Longboard Pharmaceuticals, Scott Braunstein, CEO of Marinus Pharma, and Brittany Bradrick, COO & CFO of Neurelis, Inc.
• The discussion focused on the unmet need in current standard of care for epilepsy and how the next generation of drugs can improve on older technologies
• Drug developers are looking to employ more precise pharmacology and precision medicine strategies to tailor medications to address unmet needs for each individual indication
• Looking to the future, the panelists believe we are not far from employing digital therapeutics to measure clinical progress more precisely in epilepsy, which could enhance probabilities of success in clinical trials